Biological and structural characterization of rotamers of C-C chemokine receptor type 5 (CCR5) inhibitor GSK214096

ACS Medicinal Chemistry Letters

Volumn 5, Issue 12, 2014, Pages 1296-1299

  Kazmierski, Wieslaw M ^a   Danehower, Susan ^a   Duan, Maosheng ^a   Ferris, Robert G ^a   Elitzin, Vassil ^a   Minick, Douglas ^a   Sharp, Matthew ^a   Stewart, Eugene ^a   Villeneuve, Manon ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

antagonist; atropisomer; CCR5; chemokine; entry inhibitor; GSK214096; HIV inhibitor

Indexed keywords

APLAVIROC; BMS 207940; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; GSK163929; GSK214096; PLERIXAFOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VICRIVIROC; ZM374979;

ARTICLE; CHEMOTAXIS; CHIRALITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC50; ISOMER; ULTRAVIOLET RADIATION;

EID: 84918583896     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5004124     Document Type: Article

References (27)

1. Kazmierski, W. M.; Aquino, C.; Chauder, B. A.; Deanda, F.; Ferris, R.; Jones-Hertzog, D. K.; Kenakin, T.; Koble, C. S.; Watson, C.; Wheelan, P.; Yang, H.; Youngman, M. Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1 J. Med. Chem. 2008, 51, 6538-6546
2. Kazmierski, W. M.; Anderson, D. L.; Aquino, C.; Chauder, B. A.; Duan, M.; Ferris, R.; Kenakin, T.; Koble, C. S.; Lang, D. G.; McIntyre, M. S.; Peckham, J.; Watson, C.; Wheelan, P.; Spaltenstein, A.; Wire, M. B.; Svolto, A.; Youngman, M. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile J. Med. Chem. 2011, 54, 3756-3767
3. Tsibris, A. M. N.; Kuritzkes, D. R. Chemokine antagonists as therapeutics: Focus on HIV-1 Annu. Rev. Med. 2007, 58, 445-459
4. Haskell, C. A.; Horuk, R. Lymphocyte Trafficking in Health and Disease. In Progress in Inflammation Research; Badolato, R.; Sozzani, S., Eds.; Birkhäuser: Basel, Switzerland, 2006; pp 181-196.
5. Zlotnik, A. Chemokines and cancer Int. J. Cancer 2006, 119, 2026-2029
6. Wells, T. N. C.; Power, C. A.; Shaw, J. P.; Proudfoot, A. E. I. Chemokine blockers: Therapeutics in the making? Trends Pharmacol. Sci. 2006, 27, 41-47
7. Dorr, P.; Westby, M.; Dobbs, D.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 2005, 49, 4721-4732
8. Gómez-Reino, J. J.; Pablos, J. L.; Carreira, P. E.; Santiago, B.; Serrano, L.; Vicario, J. L.; Balsa, A.; Figueroa, M.; De Juan, M. D. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5 Arthritis Rheum. 1999, 42, 989-992
9. Fildes, J. E.; Walker, A. H.; Howlet, R.; Bittar, M. N.; Hutchinson, I. V.; Leonard, C. T.; Yonanemail, N. Donor CCR5 Δ32 polymorphism and outcome following cardiac transplantation Transplant. Proc. 2005, 37, 2247
10. Ajuebor, M. N.; Aspinall, A. I.; Zhou, F.; Le, T.; Yang, Y.; Urbanski, S. J.; Sidobre, S.; Kronenberg, M.; Hogaboam, C. M.; Swain, M. G. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells J. Immunol. 2005, 174, 8027-8037
11. Ajuebor, M. N.; Carey, J. A.; Swain, M. G. CCR5 in T cell-mediated liver diseases: Whats going on? J. Immunol. 2006, 177, 2039-2045
12. Ajuebor, M. N.; Wondimu, Z.; Hogaboam, C. M.; Le, T.; Proudfoot, A. E. I.; Swain, M. G. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in Murine T cell-mediated hepatitis Am. J. Pathol. 2007, 170, 1975-1988
13. Moreno, C.; Gustot, T.; Nicaise, C.; Quertinmont, E.; Nagy, N.; Parmentier, M.; Le Moine, O.; Devière, J.; Louis, H. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice Hepatology 2005, 42, 854-862
14. Jones, K. L.; Maguire, J. J.; Davenport, A. P. Chemokine receptor CCR5: from AIDS to atherosclerosis Br. J. Pharmacol. 2011, 162, 1453-1469
15. Gonzalez, E.; Kulkarni, H.; Bolivar, H.; Mangano, A.; Sanchez, R.; Catano, G.; Nibbs, R. J.; Freedman, B. I.; Quinones, M. P.; Bamshad, M. J.; Murthy, K. K.; Rovin, B. H.; Bradley, W.; Clark, R. A.; Anderson, S. A.; OConnell, R. J.; Agan, B. K.; Ahuja, S. S.; Bologna, R.; Sen, L.; Dolan, M. J.; Ahuja, S. K. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility Science 2005, 307, 14334-11440
16. LaPlante, S. R.; Edwards, P. J.; Fader, L. D.; Jakalian, A.; Hucke, O. Revealing atropisomer axial chirality in drug discovery ChemMedChem 2011, 6, 505-513
17. LaPlante, S. R.; Fader, L. D.; Fandrick, K. R.; Fandrick, D. R.; Hucke, O.; Kemper, R.; Miller, S. P. F.; Edwards, P. J. Assessing atropisomer axial chirality in drug discovery and development J. Med. Chem. 2011, 54, 7005-7022
18. Zhou, Y. S.; Tay, L. K.; Hughes, D.; Donahue, S. Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist J. Clin. Pharmacol. 2004, 44, 680-688
19. Parker, J. S.; Smith, N. A.; Welham, M. J.; Moss, W. O. New approach to the rapid parallel development of four neurokinin antagonists. Part 5. Preparation of ZM374979 cyanoacid and selective crystallisation of ZM374979 atropisomers Org. Process. Res. Dev. 2004, 8, 45-50
20. Atwood, J. D. Integrated Rate Expressions. In Inorganic and Organometallic Reaction Mechanisms; Brooks/Cole Publishing: Monterey, CA, 1985; pp 3-17.
21. Freedman, T. B.; Cao, X.; Nafie, L. A.; Kalbermatter, M.; Linden, A.; Rippert, A. J. An unexpected atropisomerically stable 1,1-biphenyl at ambient temperature in solution, elucidated by vibrational circular dichroism (VCD) Helv. Chim. Acta 2003, 86, 3141-3155
22. Stephens, P. J.; Devlin, F. J.; Pan, J.-J. The determination of the absolute configurations of chiral molecules using vibrational circular dichroism (VCD) spectroscopy Chirality 2008, 20, 643-663
23. Freedman, T. B.; Cao, X.; Dukor, R. K.; Nafie, L. A. Absolute configuration determination of chiral molecules in the solution state using vibrational circular dichroism Chirality 2003, 15, 743-748
24. Jalkanen, K. J.; Suhai, S. N -Acetyl- l -alanine N ′-methylamide: a density functional analysis of the vibrational absorption and vibrational circular dichroism spectra Chem. Phys. 1996, 208, 81-116
25. Thoma, G.; Nuninger, F.; Schaefer, M.; Akyel, K. G.; Albert, R.; Beerli, C.; Bruns, C.; Francotte, E.; Luyten, M.; MacKenzie, D.; Oberer, L.; Streiff, M. B.; Wagner, T.; Walter, H.; Weckbecker, G.; Zerwes, H.-G. Orally bioavailable competitive CCR5 antagonists J. Med. Chem. 2004, 47, 1939-1955
26. Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Blythin, D.; Cox, K.; Wagner, N. E.; Strizki, J.; Baroudy, B. M.; Dand, N. Bioorg. Med. Chem. Lett. 2003, 13, 705-708
27. McCombie, S. W.; Tagat, J. R.; Vice, S. F.; Lin, S.-I.; Steensma, R.; Palani, A.; Neustadt, B. R.; Baroudy, B. M.; Strizki, J. M.; Endres, M.; Cox, K.; Dan, N.; Chou, C.-C. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides Bioorg. Med. Chem. Lett. 2003, 567-571